Lineage Cell Therapeutics (LCTX) Operating Income Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 1,386.07% |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -16.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.73% |
| Dec 31, 2025 | -28.14% |
| Sep 30, 2025 | 1.41% |
| Jun 30, 2025 | -237.14% |
| Mar 31, 2025 | 2.34% |
| Dec 31, 2024 | 19.68% |
| Sep 30, 2024 | 42.73% |
| Jun 30, 2024 | -16.78% |
| Mar 31, 2024 | -0.29% |
| Dec 31, 2023 | 4.17% |
| Sep 30, 2023 | -27.69% |
| Jun 30, 2023 | -18.66% |
| Mar 31, 2023 | -3.85% |
| Dec 31, 2022 | 76.49% |
| Sep 30, 2022 | 23.26% |
| Jun 30, 2022 | 40.20% |
| Mar 31, 2022 | 9.28% |
| Dec 31, 2021 | -380.07% |
| Sep 30, 2021 | -1.75% |
| Jun 30, 2021 | -10.59% |